NVS is currently trading at $112.26 in the pre-market with a slight increase of 0.12%. The stock has shown a neutral trend recently, with key technical indicators suggesting a stable position.

Analyst Sentiment:

Analysts have mixed opinions on NVS. Kepler Capital and Deutsche Bank maintain a Buy rating, while Berenberg Bank has a Hold. The price target from Kepler Capital is CHF106, indicating moderate upside potential.

Recent Developments:

NVS has received FDA approval for Fabhalta, expanding its treatment portfolio. However, competition from Apellis's Empaveli could impact market share.

Conclusion:

Given the positive analyst sentiment and recent approvals, NVS presents a buying opportunity. However, caution is advised due to potential competition and regulatory challenges.

What is price prediction 2025 for NVS Stock?

Price Prediction for NVS Stock in 2025

Target Price: $115.56 - $117.75
- Reason: Based on Fibonacci resistance levels and analyst price targets, NVS stock is expected to reach this range driven by FDA approvals for Fabhalta and strong analyst sentiment.
Lower Target: $106.28
- Reason: Supported by Fibonacci support levels and mixed analyst ratings, with some firms maintaining a Hold rating.
Current Price: $112.26
- Reason: The stock is currently trading near its Fibonacci pivot point of 112.01, indicating short-term stability.

What is surpport and resistant level for NVS Stock?

The S1 support level for NVS Stock is $109.29 ,The R1 resistant level for NVS Stock is $112.91.

What is the current price of NVS Stock?

As of the end of day on 2025-04-02, the price of NVS Stock was $109.44.

What is the target price of NVS Stock?

The target price for NVS Stock according to analyst rating is 111.00, with the highest price target at 125.00 and the lowest at 97.00. Analysts have a Hold rating on NVS Stock overall.

What is the market cap of Novartis AG?

The market cap of NVS is $234.0B.

Is Novartis AG (NVS) overvalued?

Analysis and Insights

Valuation Metrics

Novartis AG (NVS) currently exhibits a trailing P/E ratio of 20.83 (Q3 2024) and 16.58 (Q4 2024), which is higher than the industry average, suggesting potential overvaluation. The EV/EBITDA ratio of 12.49 (Q3 2024) and 9.37 (Q4 2024) indicates moderate valuation levels, while the P/S ratio of 4.72 (Q3 2024) and 3.83 (Q4 2024) reflects a premium compared to some peers. The P/B ratio of 5.31 (Q3 2024) and 4.36 (Q4 2024) is elevated, further signaling overvaluation.

Recent News and Analyst Sentiment

The FDA approval of Fabhalta for C3 glomerulopathy (C3G) is a positive development, but the label restrictions may limit its market potential, leaving room for competitors like Apellis’ Empaveli. Additionally, concerns over high levies on pharmaceutical manufacturers in the UK could impact Novartis' profitability. Analyst sentiment is mixed, with UBS downgrading NVS to Neutral with a lower price target of CHF 104, while Kepler Capital and Deutsche Bank maintain a Buy rating with targets of CHF 106 and CHF 104, respectively.

Stock Performance and Dividend Yield

NVS stock is trading at $112.26, near its 52-week high of $112.72, with an average trading volume of 3.91 million shares. The dividend yield of 3.25% (Q3 2024) and 3.84% (Q4 2024) is attractive, providing some downside protection.

Conclusion

Based on the elevated P/E and P/B ratios, mixed analyst sentiment, and regulatory headwinds, NVS appears overvalued. However, its strong dividend yield and recent FDA approvals provide some support. Investors should consider waiting for a price correction or improved market conditions before entering.

What is Novartis AG (NVS)'s business?

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

What is price prediction 2030 for NVS Stock?

The price prediction for NVS stock by 2030 is expected to range between $125 and $140. This forecast is based on the company's strong pipeline of new therapies, recent FDA approvals for drugs like Fabhalta, and its diversified portfolio in kidney diseases and other specialties. However, the stock faces challenges from patent expirations, such as Entresto, which could impact growth. Analysts maintain a Moderate Buy consensus with an average price target of $140.50, suggesting upside potential.